Nasdaq

Marker Therapeutics Announces Collaboration with Cellipont Bioservices for cGMP Manufacturing of MT-601 T Cell Therapy

Marker Therapeutics, Inc. has announced a collaboration with Cellipont Bioservices to support the cGMP manufacturing of MT-601, its lead Multi-Antigen Recognizing (MAR)-T cell therapy, currently in ...
Seeking Alpha

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the ...
The Scientist

Innate Immune Cells Develop Memory with a T Cell Marker

For decades, dogma dictated that the immune system consisted of two separate branches. Cells of the innate system respond rapidly to molecular patterns shared by a broad array of pathogens. Meanwhile, ...